
Nice rejects Celgene’s drug to treat blood cancer
pharmafile | June 24, 2016 | News story | Medical Communications, Research and Development | CDF, Celgene, NICE, Vidaza, blood cancer
The National Institute for Health and Care Excellence (Nice) rejected biotech firm Celgene’s (Nasdaq: CELG) Vidaza (azacitidine) to treat a form of blood cancer.
The regulator said there was a high degree of uncertainty about azacitidine’s clinical effectiveness relative to current treatments and it could not be considered a cost-effective use of NHS resources.
The incremental cost-effectiveness ratio for azacitidine was estimated to be around £240,000 per QALY which meant it did not meet the criteria to be considered for use in the Cancer Drugs Fund (CDF). The company also stated that it did not intend to submit a case for including azacitidine in the CDF.
The drug is indicated for acute myeloid leukaemia. Celgene does not intend to submit a case for including azacitidine in the CDF, the regulator said.
Anjali Shukla
Related Content

NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma
NICE has published final draft guidance recommending daratumumab with bortezomib, lenalidomide and dexamethasone (D-VRd) for …

NICE recommends allergy immunotherapy tablets for younger children
NICE has recommended two sublingual immunotherapy tablets for children with moderate to severe allergic rhinitis …

NICE backs atogepant for acute migraine treatment
NICE has issued Final Draft Guidance recommending AbbVie’s AQUIPTA (atogepant) as an option for the …





